Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Takeda And Affymax Recall Anemia Drug
by Ann M. Thayer
March 4, 2013
| A version of this story appeared in
Volume 91, Issue 9
Affymax and its Japanese partner Takeda Pharmaceutical have voluntarily recalled the anemia drug Omontys after about a year on the U.S. market. In late March 2012, FDA approved the PEGylated synthetic peptide as a treatment for anemia due to chronic kidney disease in adults. The recall came after five of 25,000 dialysis patients died as a result of serious hypersensitivity reactions. Omontys was the only product of 12-year-old Affymax, a business formerly owned by GlaxoSmithKline. Omontys competed with other erythropoiesis-stimulating protein drugs, such as Amgen’s Epogen and Aranesp.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter